Prelude Therapeutics Incorporated
PRLDPrelude Therapeutics Incorporated is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company specializes in designing small molecule inhibitors to treat various cancers, leveraging innovative precision medicine approaches to improve patient outcomes.
Company News
Prelude Therapeutics announced preclinical data for PRT13722, a first-in-class oral KAT6A degrader showing complete tumor regressions in HR+/HER2- breast cancer models with improved hematological safety compared to existing approaches. The company remains on track to file an IND application by mid-2026 and initiate clinical trials in the second h...
Prelude Therapeutics presented preclinical data on two promising therapeutic approaches for myeloproliferative neoplasms (MPNs): a JAK2V617F-selective JH2 inhibitor (PRT12396) and a mutant calreticulin targeted degrader antibody conjugate, demonstrating potential disease-modifying capabilities.
Prelude Therapeutics reported a Q2 2025 net loss of $31.2 million, reduced operating expenses, and focused on its oral SMARCA2 degrader program while maintaining cash reserves to fund operations into Q2 2026.
Prelude Therapeutics announced positive initial clinical data for its SMARCA2 degrader PRT3789 in a Phase 1 trial, showing promising anti-tumor activity and a generally well-tolerated safety profile in patients with SMARCA4-mutated cancers.
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
